menu
    • menu

    Company profile for Citryll

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Citryll BV is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Target diseases include SLE, RA, vasculitis, cancer and fibrosis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CitryllNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Oss, Noord-Brabant 5349 AE , NL
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://citryll.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/citryll/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Citryll Present CIT-013 Phase I Results In Rheumatoid Arthritis
    Citryll Present CIT-013 Phase I Results In Rheumatoid Arthritis

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174302/0/en/Citryll-Presents-Positive-Data-from-Phase-I-Study-of-CIT-013-in-Rheumatoid-Arthritis-at-ACR-Convergence-2025.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Citryll Initiates Ph 2A Trial for CIT-013 in Rheumatoid Arthritis
    Citryll Initiates Ph 2A Trial for CIT-013 in Rheumatoid Arthritis

    02 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/02/3142324/0/en/FIRST-PATIENT-DOSED-IN-CITRYLL-S-PHASE-IIA-TRIAL-EVALUATING-CIT-013-IN-RHEUMATOID-ARTHRITIS.html

    GLOBENEWSWIRE
    02 Sep 2025
    Share Share
    Citryll Forms New Scientific Advisory Board
    Citryll Forms New Scientific Advisory Board

    24 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/24/3120752/0/en/Citryll-Announces-Formation-of-Scientific-Advisory-Board.html

    GLOBENEWSWIRE
    24 Jul 2025
    Share Share
    Citryll Expands CIT-013’s Potential For Treating Inflammatory Disorders
    Citryll Expands CIT-013’s Potential For Treating Inflammatory Disorders

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/20/3029312/0/en/Citryll-Demonstrates-a-Broader-Therapeutic-Potential-for-CIT-013-in-the-Treatment-of-Inflammatory-Disorders.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    Citryll Raises EUR 85 Million for NET-Targeting Therapy
    Citryll Raises EUR 85 Million for NET-Targeting Therapy

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993455/0/en/Citryll-Raises-EUR-85-Million-Series-B-to-Advance-Novel-NET-Targeting-Therapy-for-Immune-Mediated-Inflammatory-Disorders.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Citryll Gets Grant For NET Research In Rheumatoid Arthritis
    Citryll Gets Grant For NET Research In Rheumatoid Arthritis

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957432/0/en/Citryll-and-leading-rheumatology-centres-receive-Reumanederland-grant-to-collaborate-on-NET-research-to-advance-novel-treatments-for-rheumatoid-arthritis.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search